Dianthus Therapeutics, Inc. DNTH 深 沪
等待开盘 10-15 09:30:00 美东时间
74.76
-2.820
-3.63%
华盛通- 最 高78.78
- 今 开77.17
- 成交量 97.73万股
- 最 低 74.47
- 昨 收 77.58
- 总市值 41.82亿
- 52周最高 117.875
- 市盈率 静 --
- 换手率 1.75%
- 52周最低 32.28
- 委 比 42.93%
- 总股本 5593.44万
- 历史最高 336.00
- 量 比 1.09
- 振 幅 5.56%
- 历史最低 5.136
- 每 手 1
- 风险率 26.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give...
10-06 18:23
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156
Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.
09-04 21:12
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.
08-03 23:03
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP). An interim analysis of 40 patients completing Part A showed a 75% confirmed responder rate...
06-13 01:20
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the periphe...
06-11 21:09
今日药闻 | BI、GSK、拜耳、礼来等新进展……
1.5月6日，瑞博生物宣布与勃林格殷格翰（BI）在代谢功能障碍相关脂肪性肝炎（MASH）领域的siRNA合作达成第三个关键里程碑 此次进展标志着双方合作研发进...
05-07 17:24
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
